JAMA FEBRUARY 12, 2019

Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial

The SPRINT MIND Investigators for the SPRINT Research Group (Williamson JD, Pajewski NM, et al.)

Bottom Line

In the SPRINT-MIND trial, intensive systolic blood pressure control to a target of <120 mm Hg, compared with a standard target of <140 mm Hg, did not significantly reduce the risk of probable dementia but did significantly reduce the risk of mild cognitive impairment (MCI) and a composite outcome of MCI or probable dementia.

Key Findings

1. Intensive blood pressure control did not result in a statistically significant reduction in the primary outcome of probable dementia (HR 0.83; 95% CI 0.67–1.04; P = .10).

2. A statistically significant reduction was observed in the risk of mild cognitive impairment (HR 0.81; 95% CI 0.69–0.95).

3. A statistically significant reduction occurred in the composite outcome of mild cognitive impairment or probable dementia (HR 0.85; 95% CI 0.74–0.97).

Study Design

Design

RCT

Open-Label

Sample

9,361

Patients

Duration

3.34 yr (median)

Median

Setting

Multicenter, US

Population Adults aged 50 years or older with hypertension but without diabetes or history of stroke

Intervention Intensive blood pressure treatment targeting systolic BP <120 mm Hg

Comparator Standard blood pressure treatment targeting systolic BP <140 mm Hg

Outcome Incidence of adjudicated probable dementia

Study Limitations

• The trial was terminated early due to the success of cardiovascular outcomes, resulting in a shorter duration of the intensive blood pressure intervention (median 3.34 years) than originally planned.

• The number of observed cases of probable dementia was lower than the original statistical power calculation required, limiting the ability to detect a significant difference.

• The study population excluded patients with a history of stroke or diabetes, limiting the generalizability of the findings to these high-risk groups.

Clinical Significance

While the impact on clinically diagnosed dementia remains inconclusive due to limited duration, the study provides robust evidence that aggressive systolic blood pressure management is a potentially modifiable strategy to reduce the incidence of mild cognitive impairment in older hypertensive adults.

Historical Context

The SPRINT trial was initially designed to evaluate cardiovascular and renal outcomes of intensive blood pressure lowering. Because hypertension is a recognized vascular risk factor for cognitive decline, the SPRINT-MIND sub-study was pre-specified to investigate whether this same intensive management could provide neuroprotective benefits, addressing the lack of prior randomized trial evidence for dementia prevention via blood pressure control.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the primary pathophysiological mechanisms by which chronic hypertension contributes to cognitive decline and the development of vascular dementia?

Key Response

Hypertension causes structural changes in the cerebral microvasculature, including lipohyalinosis and fibrinoid necrosis, leading to chronic hypoperfusion and blood-brain barrier disruption. This results in white matter hyperintensities (leukoaraiosis) and lacunar infarcts, which disrupt the subcortical-cortical circuits essential for executive function and memory.

Resident

In an elderly patient with hypertension and early signs of memory loss, how do the results of SPRINT-MIND influence your choice of blood pressure targets compared to standard JNC-8 or ACC/AHA 2017 targets?

Key Response

While standard guidelines often suggest targets of <130/80 or <140/90, SPRINT-MIND suggests that intensive control (<120 mmHg) significantly reduces the risk of Mild Cognitive Impairment (MCI) (HR 0.81). Residents must balance this neuroprotective benefit against the increased risks of adverse events observed in SPRINT, such as hypotension, syncope, and acute kidney injury.

Fellow

The primary outcome for 'probable dementia' in SPRINT-MIND was not statistically significant (p=0.055), yet the composite outcome of MCI or dementia was significant. How should a subspecialist interpret this 'near-miss' in the context of the trial's early termination?

Key Response

The SPRINT trial was stopped early due to the overwhelming cardiovascular benefit in the intensive arm. Because dementia has a longer latency period than cardiovascular events, the early termination likely underpowered the study to detect a significant difference in probable dementia. The significant reduction in MCI, a precursor to dementia, strongly suggests a true neuroprotective effect that might have reached significance for dementia with longer follow-up.

Attending

How does the evidence from SPRINT-MIND shift the clinical paradigm from viewing hypertension management solely as 'stroke prevention' to a more comprehensive 'brain health' strategy?

Key Response

Traditionally, BP management focused on preventing acute events like ICH or ischemic stroke. SPRINT-MIND provides Level 1 evidence that intensive BP control can modify the trajectory of subclinical cognitive decline (MCI). This shifts the teaching point toward long-term preservation of functional independence and the mitigation of the public health burden of the dementia continuum.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the statistical and longitudinal implications of using MCI as a secondary outcome in SPRINT-MIND, given the high rate of reversion from MCI to normal cognition in elderly populations.

Key Response

MCI is a heterogeneous and unstable diagnostic construct; many participants labeled with MCI may return to baseline or fluctuate. A PhD-level critique would focus on whether the trial's adjudication process accounted for this volatility and how the competing risk of death—which was lower in the intensive group—might have influenced the observed incidence of cognitive impairment (the 'survivor bias').

Journal Editor

As a reviewer, how would you address the potential for 'detection bias' in SPRINT-MIND, considering that participants in the intensive arm had more frequent clinic visits and potential for adverse event monitoring?

Key Response

If the intensive arm had more frequent interactions with healthcare providers, there was a higher chance for subtle cognitive changes to be noticed or for confounding medications to be adjusted. Editors would look for evidence that the cognitive adjudication committee was strictly blinded to treatment assignment and that the interval of cognitive testing was identical across both arms to ensure the validity of the HR.

Guideline Committee

Should the SPRINT-MIND data warrant a 'Class I' recommendation for intensive BP control (<120 mmHg) for the specific indication of preventing Mild Cognitive Impairment, and how does this conflict with the lack of significance for 'probable dementia'?

Key Response

Guideline committees (like those for ACC/AHA) must decide if a significant secondary outcome (MCI) in a trial where the primary outcome (Dementia) failed is sufficient for a recommendation. Currently, most guidelines maintain a 130/80 target for general health but acknowledge SPRINT-MIND as supporting intensive control for brain health. A Class IIa recommendation is more likely, as the primary endpoint of dementia was not met, preventing a Class I designation.

Clinical Landscape

Noteworthy Related Trials

2008

ACCORD-MIND Trial

n = 2,977 · Neurology

Tested

Intensive glycemic control and intensive blood pressure control

Population

Adults with type 2 diabetes at high risk for cardiovascular events

Comparator

Standard glycemic control and standard blood pressure control

Endpoint

Change in cognitive performance measured by Digit Symbol Substitution Test

Key result: Neither intensive glucose control nor intensive blood pressure control showed a significant benefit in slowing cognitive decline over 40 months.

2015

SPRINT Trial

n = 9,361 · NEJM

Tested

Intensive systolic BP target <120 mmHg

Population

Hypertensive patients at increased cardiovascular risk without diabetes

Comparator

Standard systolic BP target <140 mmHg

Endpoint

Composite of myocardial infarction, acute coronary syndrome, stroke, acute decompensated heart failure, or death from CV causes

Key result: Intensive blood pressure control significantly reduced cardiovascular events and all-cause mortality compared to standard treatment.

2016

HOPE-3 Trial

n = 12,705 · NEJM

Tested

Rosuvastatin, candesartan/hydrochlorothiazide, or both

Population

Intermediate-risk individuals without known cardiovascular disease

Comparator

Placebo

Endpoint

Composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke

Key result: Treatment with blood-pressure-lowering medication reduced cardiovascular events in the overall population, particularly among those with elevated systolic BP.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis